ebomi
Colour theme
Sign in
Insider · CIK 0001277994

Venrock Entrepreneurs Fund IV L P

CIK 0001277994 Name as filed on the most recent filing

Filed as Venrock Entrepreneurs Fund IV L P (12)

23 transaction lines · from 12 filings · filed 2010-04-28 to 2019-10-28 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2019-10-28 S, Open-market sale Bellerophon Therapeutics, Inc.BLPH 146,091, disposed Open Form 4 filing 0001209191-19-054264
2019-10-25 S, Open-market sale Bellerophon Therapeutics, Inc.BLPH 25,511, disposed Open Form 4 filing 0001209191-19-054264
2019-10-24 S, Open-market sale Bellerophon Therapeutics, Inc.BLPH 353,354, disposed Open Form 4 filing 0001209191-19-054264
2019-01-23 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 100,000, acquired Open Form 4 filing 0001209191-19-019526
2018-09-17 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 70,944, acquired Open Form 4 filing 0001209191-18-051215
2018-09-14 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 92,250, acquired Open Form 4 filing 0001209191-18-051215
2018-09-13 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 89,160, acquired Open Form 4 filing 0001209191-18-051215
2018-09-12 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 85,913, acquired Open Form 4 filing 0001209191-18-050736
2018-09-11 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 228,840, acquired Open Form 4 filing 0001209191-18-050736
2018-09-10 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 243,640, acquired Open Form 4 filing 0001209191-18-050736
2018-09-07 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 53,742, acquired Open Form 4 filing 0001209191-18-050122
2018-09-06 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 42,095, acquired Open Form 4 filing 0001209191-18-050122
2018-09-05 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 42,325, acquired Open Form 4 filing 0001209191-18-050122
2018-08-16 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 43,109, acquired Open Form 4 filing 0001209191-18-047212
2018-08-15 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 175,902, acquired Open Form 4 filing 0001209191-18-047212
2018-08-14 P, Open-market purchase Bellerophon Therapeutics, Inc.BLPH 123,868, acquired Open Form 4 filing 0001209191-18-047212
2013-11-15 S, Open-market sale Anacor Pharmaceuticals, Inc.ANAC 2,109,000, disposed Open Form 4 filing 0001277997-13-000004
2012-09-20 S, Open-market sale Anacor Pharmaceuticals IncANAC 121,457, disposed Open Form 4 filing 0001277997-12-000004
2012-09-14 S, Open-market sale Anacor Pharmaceuticals IncANAC 227,805, disposed Open Form 4 filing 0001277997-12-000003
2012-09-13 S, Open-market sale Anacor Pharmaceuticals IncANAC 98,330, disposed Open Form 4 filing 0001277997-12-000002
2012-09-11 S, Open-market sale Anacor Pharmaceuticals IncANAC 67,603, disposed Open Form 4 filing 0001277997-12-000002
2010-11-30 P, Open-market purchase Anacor Pharmaceuticals IncANAC 3,000,000, acquired Open Form 4 filing 0001277997-10-000005
2010-04-27 P, Open-market purchase Alimera Sciences IncALIM 3,366,781, acquired Open Form 4 filing 0001277997-10-000003

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. VENROCK ENTREPRENEURS FUND IV L P, insider transactions. Retrieved 2026-08-23 from https://ebomi.com/insider/0001277994

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.